Methiopropamine

Methiopropamine (MPA) is listed as a drug in Schedule 4, item 138B of the Customs (Prohibited Imports) Regulations 1956. Its importation into Australia is prohibited unless the importer holds both an import licence and an import permission. The definition of “drug” also covers relevant isomers, derivatives including salts, and non-exempt preparations containing them. The Office of Drug Control classifies MPA as a narcotic and requires an export licence and permit;¹¹ domestic possession, supply and manufacture are governed by separate State and Territory laws.

The current official Shenzhen Public Security Bureau portal expressly lists MPA as entry 25 of the 2025 non-medical narcotic and psychotropic directory. Article 4 of the current national regulation permits non-medical controlled substances only for legally authorized experimental research and prohibits production, dealing, use, storage, and transport. This supports the canonical status prohibited, rather than ordinary prescription-only or unscheduled. The supplied China dossier was about alpha-PVP, not methiopropamine; it was read but is not used as evidence for this substance. This result is limited to mainland China's national directories and the law as available on 2026-08-27; lawful authorized research is not ordinary public access.

The current e-Sbírka rendition inspected on 27 August 2026 identifies itself as current from 25 June 2026 and lists Methylthienylpropamin / MPA / N-methyl-1-(thiofen-2-yl)propan-2-amin in the psychotropic-substance schedule. The canonical prohibited label means unauthorized handling under the addictive-substance schedule, not an absolute ban on every licensed scientific or very limited therapeutic activity. The cited texts do not enumerate individual permit holders, enforcement outcomes, or any product authorization; no ordinary consumer, recreational or general commercial exception was located.

Italy's Ministry of Health expressly inserted MPA (methiopropamine) into Table I, identifying its chemical name and the alternative names Metiopropamina and Metiltienpropamina. The decree became effective on the fifteenth day after publication (27 July 2018). The current Normattiva view reports the consolidated D.P.R. 309/1990 as vigente al 27/08/2026 and last updated 06/08/2026. Article 14 states that Table I includes substances with established risks of physical or psychological dependence and applies the regime to listed substances in every product, mixture or preparation form; Article 73 separately provides criminal penalties for specified unauthorized dealings in Table I substances. This supports the canonical prohibited classification, but does not attempt a fact-specific analysis of personal-use treatment, authorization, or penalty exceptions.

As of 27 August 2026, the current official BetmVV-EDI schedule expressly identifies MPA by name, synonym, chemical name and GTIN in Verzeichnis d. BetmKV defines Verzeichnis d as prohibited controlled substances. This is a schedule/prohibition classification, not a product-level prescription classification: the substance listing alone does not create an authorised medicine or an ordinary pharmacy route. BetmVV-EDI Article 1(2) extends control to listed substances' salts, esters, ethers, carbamates, stereoisomers, certain salts/derivatives of those stereoisomers, and preparations containing them; it does not establish that unrelated constitutional analogues are covered. The BetmKV PDF directly inspected is consolidated to 1 January 2022, so its category and permit provisions are cited with that currency limitation; the current 13 March 2026 schedule itself was inspected in both PDF and authoritative Fedlex XML. This is a current-law research snapshot, not legal advice.

Methiopropamine is expressly identified in the current UAE Legislation portal's indexed Schedule No. (6) as item 17, with the chemical name N-Methyl-1-(2-thienyl)-2-propanamine. Article 11 prohibits import, export, transfer, production, manufacture, bringing into the UAE, possession, acquisition and other handling of Schedule 6 psychotropic substances except in authorized cases and under stipulated conditions. Article 12 separately prohibits addiction or personal use except treatment under the Article 40 prescription framework. The Article 10 medical/scientific exception is indexed for Schedules 1, 2, 4 Section 1 and 5, not Schedule 6. No inspected official source establishes an approved MPA medicine, routine prescription product or substance-specific Schedule 6 research route. The EDE traveler/medicine service therefore must not be treated as permission to import or possess MPA. Direct UAE Legislation downloads returned HTTP 403 to the reader; the official portal's indexed schedule and article text were inspected, and the current Arabic attachments should be confirmed before a product-specific, court-facing or border decision. This is a scheduling classification, not a fact-specific penalty or authorization opinion.

The packet's Illegal disposition is supported and should be made precise: MPA is expressly named in the current Argentine individual estupefaciente list, rather than controlled only through an analogue inference. Unauthorized or illicit-purpose production, preparation, commerce, distribution, storage, transport, supply and import are criminalized, and possession is separately punishable; the statute has a fact-specific lower penalty for unequivocal personal-use possession, not a blanket legalization or safe harbor. ANMAT's current table places METIOPROPAMINA, MPA in Ley 19.303 Lista II and leaves the Ley 17.818 column blank. Lista II permits only tightly regulated authorized medical/research handling and prescription, not consumer or over-the-counter access. No approved or marketed MPA medicinal product was established by the inspected sources. Identity limitations remain: the current decree attachment does not state stereochemistry, salt, hydrate/solvate, purity threshold or mixture rules, and a sample reported only as MPA requires confirmatory analytical identification. This is primary-source legal-information research, not an individualized legal opinion.

The current official consolidated Decreto 867 text expressly lists methiopropamine under the Spanish name Metiopropamina and chemical name N-metil-1-(tiofen-2-il)propan-2-amina in Article 1. Decreto 416's first article identifies this exact substance among the substances incorporated into Article 1 and records publication on 02-Sep-2017. Because Article 1 is the severe-effects category referenced by Ley 20.000 Article 1, the result is normalized to prohibited rather than analog_covered, prescription_only or unscheduled. Ley 20.000 Articles 1 and 3 penalize unauthorized manufacture and trafficking, and Article 4 provides only a limited small-quantity treatment or exclusive, proximate personal-use justification; that limited rule does not remove the Article 1 classification. The current schedule also expressly extends listed substances to their isomers, esters, ethers and salts unless excepted; this text-based extension is not a blanket finding that every structurally similar analogue is controlled. No claim is made here about an authorized medicinal product or future regulatory amendments.

Supported correction of the legacy Restricted label to canonical restricted_other. Resolución 000116's operative Annex Technical 1 is headed 'Listado de sustancias incluidas como sustancias de control especial y sometidas a fiscalización' and expressly lists METIOPROPAMINA (MPA) as item 311 with the N,α-dimethyl-2-thiophene ethanamine hydrochloride designation and Green List II classification. The listing establishes national fiscalization and controlled handling; the inspected instruments do not establish a blanket criminal prohibition for every act, an approved prescription-medicine status, or a general analogue rule. Annex Technical 4 rule 5 extends control to chemically possible salts and stereoisomers of Green List II substances unless expressly excepted.

The existing entry is directionally correct but uses an uncited generic description. The current ANSM compilation expressly names Méthiopropamine/MPA in the narcotics list and attributes the entry to the 3 October 2017 amendment. The Ministry of Health's PEPPS operational summary states that, absent express authorization, production, manufacture, transport, import, export, detention, offer, transfer, acquisition and use involving substances classified as narcotics are prohibited. Thus the supported canonical status is prohibited, covering the entry's possession, purchase/acquisition, sale/transfer and manufacture statements. The ANSM PDF is expressly an information-only consolidation: the legally opposable materials are the amended 22 February 1990 arrêté and published ANSM Director-General decisions. This is legal-information research, not an individualized legal opinion; authorized medical products and fact-specific exceptions require separate analysis.

The exact name methiopropamine and designation MPA appear together in the current official List I table, so this is an express named listing rather than an analogue or schedule-silence inference. Article 2 makes the listed-substance prohibitions apply to import, export, preparation, processing, sale, supply, transport, possession and manufacture. For a packet, Article 1(4) expressly includes bringing into the Netherlands the goods in which a List I means is packed or stored, and handling directed to onward transport, storage, delivery, receipt or transfer. This supports a prohibited packet-import disposition. The result concerns the exact listed substance and does not independently classify any different analogue, positional isomer, metabolite or formulation. It also does not convert the Opiumwet criminal-control status into a medicine or ordinary prescription classification. This is legal-information research, not individualized legal advice.

The existing entry is directionally correct but needs its official schedule citation and legal disposition. MPA is a named II-P psychotropic substance, not merely an unlisted analogue or generic new psychoactive substance. Under Article 33(1), group II-P psychotropics may be used only for medical, industrial or research purposes; Article 34(1) limits possession to an authorized entrepreneur, organizational unit or person, and Article 62(1) criminalizes possession contrary to the Act. The result is therefore the canonical prohibited status for ordinary possession, acquisition and use, while preserving the statutory authorization exceptions. Article 41(2) requires specially marked prescriptions or requisitions for pharmacy dispensing of preparations containing psychotropic substances; its ordinary-prescription exception is limited to groups III-P and IV-P, so it does not make II-P MPA an ordinary prescription-only substance. The exact-name RPL query returned no active MPA/Metiopropamina substance entry; this is not proof that no future or synonym-described medicinal product could exist.

The packet's conclusion that MPA is illegal is supported, but the legal mechanism should be stated precisely: the fetched current List I text contains the parent class 2-Тиофен-2-илэтиламин and its derivatives, while MPA was not found as a separately named entry in that PDF. MPA's stated structure (N-methyl-1-(thiophen-2-yl)propan-2-amine) is obtained from the parent 2-(thiophen-2-yl)ethylamine by formal methyl substitutions at the amino nitrogen and the adjacent carbon; under Note 6 this is the relevant derivative analysis, subject to the note's exclusions and atom-count conditions. List I is a prohibition on circulation, not merely a prescription or accounting restriction. The Roszdravnadzor PDF is expressly consolidated only through 11 June 2025 (the page was accessed 2026-08-27); an official publication-portal retrieval for later amendments was unavailable in this pass. The packet's historical attribution to Government Resolution No. 822 of 6 October 2011 was not independently quoted because the official publication endpoint timed out, so the result relies on the current consolidated List I text and does not assert a verified insertion date. This is legal-information research, not individualized legal advice; exact sample identity, salt/isomer, state-medicines-register status and any statutory scientific/official-use exception require separate verification.

The current official Swedish Medical Products Agency consolidated schedule expressly lists Metiopropamin (MPA), chemical name N-methyl-1-(thiophen-2-yl)propan-2-amine, with Swedish list I and international P II. List I is defined in the schedule as covering substances, plant material and fungi that normally have no medical use. The Swedish Narcotic Drugs Control Act permits narcotics handling only for the listed authorized purposes and restricts possession to specified authorized persons; the Narcotic Drugs Penal Law criminalizes unauthorized possession and use as well as other listed handling. Accordingly, the packet's 'Illegal' disposition is supported and normalized to canonicalStatus prohibited. This is a general statutory disposition, not individualized legal advice; authorization, scientific or industrial exceptions require separate permits or statutory conditions.